Biogen | BIIB - Equity Capital And Reserves


Biogen reported $18.21B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
ALKERMES USD 1.82B 85.86M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Bayer EUR 25.95B 3.75B Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 8.65B 680M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025